A phase 2 trial of porustobart in microsatellite-stable colon cancer is due to start enrolling patients this year. (iStock / Getty Images Plus) Solstice Oncology has secured $225 million in series A ...
Agenus Inc. has surged >195% YTD, driven by optimism around its BOT/BAL combo therapy for MSS colon cancer. Read more on AGEN ...
Immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies have transformed the treatment of many cancers, yet ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating ...
3d
How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story
Pfizer Canada and BioNTech announced Health Canada’s approval of the Omicron XFG‑adapted COMIRNATY vaccine for individuals ...
Agenus is now a pure-play on its BOT/BAL cancer immunotherapy, with all resources focused on the upcoming ROBBIN Phase 3 ...
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026ADG138 is a ...
GlobalData on MSN
Akeso begins Phase III study of cadonilimab for gastric cancer
The antibody targets patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Detailed price information for Adagene Inc ADR (ADAG-Q) from The Globe and Mail including charting and trades.
Akeso, Inc. (9926.HK), a biopharmaceutical company, announced that it has enrolled the first patient in COMPASSION-37 (AK104-311), a phase 3 trial evaluating Cadonilimab as first-line treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results